OREANDA-NEWS. Fresenius expects new records for sales and earnings in the current business year. At the Annual General Meeting in Frankfurt today, Ulf Mark Schneider, CEO of Fresenius, confirmed the 2016 targets. The company is forecasting sales growth of 6 to 8 percent and an increase of 8 to 12 percent in net income, both in constant currency.

In his speech, Schneider also confirmed the company’s mid-term financial goals: “For fiscal 2019 we are targeting sales of €36 to €40 billion, and net income between €2 and €2.25 billion. This means a doubling of our net income within a period of just five years, and a fourfold increase in one decade.”

Schneider said that by combining a disciplined growth focus with operational and structural stability, the company has built a solid basis for excellent long-term performance. “2015 marked our 12th consecutive record year and delivered our 23rd straight dividend increase,” the Fresenius CEO added. “These results demonstrate that we are continuing to generate strong, stable growth over time.”

Shareholders approved with a majority of 90.68% the 23rd consecutive dividend increase proposed by the general partner and the Supervisory Board. The dividend was raised by 25% to €0.55 per share.

With clear majorities, the shareholders elected all candidates for a new Supervisory Board. Prof. Dr. med. Iris L?w-Friedrich, Chief Medical Officer and Executive Vice President of UCB S.A., and Hauke Stars, a Member of the Management Board of Deutsche B?rse AG, were elected to the 12-member body for the first time, as shareholder representatives.

Shareholder majorities of 99.64% and 99.52%, respectively, approved the actions of the Management and Supervisory Boards in 2015.

At the Annual General Meeting, 72.73% of the subscribed capital was represented.